2nd Aug 2022 18:01
C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Says it has made continued progression across its drug discovery portfolio. Says it is in advanced stage commercial discussions for its NRF2 activator programme for inflammatory diseases with a deal anticipated in the second half of 2022. Also says its MALT-1 inhibitor programme for haematological and solid tumours has compounds, that match the leading clinical candidate in terms of in vitro and in vivo profile, is now moving towards identifying a "best-in-class shortlist of compounds". Read More